Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to treatment start:\r\n* Known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)/cytochrome P450, family 3, subfamily A, polypeptide 4 (5), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* That have a known risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations/medications, dietary supplements
Currently receiving any of the following medications and cannot be discontinued 7 days prior to starting the study\r\n* Herbal supplements including grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each; orange juice is allowed\r\n* Known strong inducers or inhibitors of CYP3A4/5 including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges\r\n* Medications known to have a narrow therapeutic window and are predominantly metabolized through CYP3A4
In general, the use of any concomitant medication deemed necessary for the care of the patient is permitted in this study, except as specifically prohibited below; combination administration of study drugs could result in drug-drug interactions (DDI) that could potentially lead to reduced activity or enhanced toxicity of the concomitant medication and/or ribociclib; patient is currently receiving any of the following medications and cannot discontinue use within 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Herbal preparations/medications\r\n* Dietary supplements
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to treatment:\r\n* Known strong inducers or inhibitors of CYP3A4/5 or bile salt pump efflux, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges;\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes;\r\n* Herbal preparations/medications, dietary supplements;\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
Patient receiving any of the following medications within 7 days of day 1 of study treatment:\r\n* Known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes\r\n* Herbal preparations/medications
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Herbal preparations/medications, dietary supplements; acceptable supplements include multivitamins, vitamin D and calcium\r\n* Angiotensin-converting enzyme (ACE) inhibitor therapy
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges, that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Herbal preparations/medications, dietary supplements
Currently receiving treatment, including medications and herbal preparations with known strong inducers or inhibitors of cytochrome p450 enzymes cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) medications that have a narrow therapeutic window and are predominately metabolized through CYP3A4/5 or herbal preparations/medications, dietary supplements, which cannot be discontinued at least one week prior to receiving investigational drug; anti-retrovirals, anti-microbials, and anti-arrhythmics are the most common medications that interact with these enzymes
Currently receiving any of the following that cannot be discontinued at least 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Medications with a narrow therapeutic window that are predominantly metabolized through CYP3A4/5\r\n* Herbal supplements, such as St. Johnâ€™s wort; the use of marijuana or its derivatives is allowed in States with statutes permitting the use of recreational or medical marijuana
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Herbal preparations/medications, dietary supplements
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug\r\n* Known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Herbal preparations/medications, dietary supplements
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of cytochrome P450 family 3 subfamily A member 4/5 (CYP3A4/5), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes\r\n* Herbal preparations/medications, dietary supplements not prescribed by a medical doctor (MD)
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug (for details):\r\n* Known strong inducers or inhibitors of CYP3A4/5 including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Those have a narrow therapeutic window and are predominantly metabolized through CYP3A4\r\n* Those have a known strong risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations
Patient is currently receiving any of the prohibited substances that cannot be discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5; medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5; systemic corticosteroids ? 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued or replaced by safe alternative medication.
Patient is currently receiving any of the following medications and cannot be discontinued =< 7 days prior to starting study drug: known strong inducers or inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges or that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 or herbal preparations/medications or dietary supplements
Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
Those have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Those having a narrow therapeutic window and are predominantly metabolized through CYP3A4/5\r\n* Those having a known risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations/medications
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug: a. Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges. b. That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. c. Herbal preparations/medications, dietary supplements. d. Hormone replacement therapy, topical estrogens (including any intra-vaginal preparations), megestrol acetate and selective estrogen-receptor modulators (e.g. raloxifene).
That have a narrow therapeutic window and are predominantly metabolized through CYP3A4.
Patients who are currently receiving treatment with agents that are metabolized predominantly through CYP3A4 and that have a narrow therapeutic window.
Patient is currently receiving any of the prohibited substances that cannot be discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5; medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5; systemic corticosteroids ? 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued or replaced by safe alternative medication.
